Tango Therapeutics shares surge 7% as investors focus on cash-rich pipeline
$343 million cash runway into 2028 and vopimetostat trial progress overshadow Q4 loss
Tango Therapeutics shares climbed 7.4% on Thursday as investors looked past the company's quarterly losses to focus on its strengthened financial position and advancing cancer treatment pipeline, which includes a pivotal trial scheduled for 2026.
The clinical-stage biotechnology company reported a net loss of $38.7 million, or $0.29 per share for the fourth quarter of 2025. Despite the losses, the stock gained ground as the company revealed it held $343.1 million in cash, cash equivalents, and marketable securities as of December 31, 2025—enough capital to fund operations into 2028.
That financial runway extends well beyond key clinical catalysts coming in the next two years, a fact that appears to have resonated with investors looking for visibility on the company's path to potential commercialization. Tango's primary asset, vopimetostat (TNG462), is a PRMT5 inhibitor targeting MTAP-deleted cancers, a synthetic lethality approach that has gained attention in the oncology field for its precision targeting.
The company said it plans to initiate a pivotal Phase 2/3 study for vopimetostat monotherapy in second-line MTAP-deleted pancreatic cancer in 2026, targeting approximately 300 patients who have received one prior line of therapy. The trial will compare vopimetostat (250 mg once daily) against standard chemotherapy regimens, according to clinical trial information.
Pancreatic cancer remains one of the most lethal malignancies, with limited treatment options for patients who progress beyond first-line therapy. The MTAP deletion occurs in approximately 15% of pancreatic cancers and 10-15% of solid tumors overall, creating a defined patient population for Tango's targeted approach.
Beyond the monotherapy trial, Tango is advancing combination strategies. The company expects initial Phase 1/2 safety and efficacy data in 2026 from a study combining vopimetostat with Revolution Medicines' RAS(ON) inhibitors in MTAP-deleted, RAS-mutated pancreatic and lung cancers. RAS mutations are among the most common oncogenic drivers, and their co-occurrence with MTAP deletions creates what researchers describe as a synthetic dependency that could make tumors more vulnerable to dual pathway inhibition.
Adding to the combination strategy, Tango announced a clinical collaboration with Erasca to evaluate vopimetostat with ERAS-0015, Erasca's pan-RAS molecular glue. The Phase 1/2 trial will target patients with MTAP-deleted pancreatic or MTAP-deleted RAS-mutant non-small cell lung cancer. Under the agreement, Tango will sponsor the trial while Erasca provides ERAS-0015 at no cost, with both companies retaining commercial rights to their respective compounds.
The scientific rationale for the combination stems from the observation that nearly all MTAP-deleted pancreatic cancers and 30% of MTAP-deleted NSCLC tumors also harbor RAS mutations. By simultaneously inhibiting RAS signaling and PRMT5, the companies aim to achieve deeper and more durable responses while reducing the emergence of resistance in these hard-to-treat cancers.
Analysts remain broadly positive on Tango's prospects, with an average price target of $15.67—representing approximately 27% upside from Thursday's closing price of $12.35. The stock has recovered significantly from its 52-week low of $1.03, though it remains below its 52-week high of $13.60 reached earlier this year.
The company also announced several leadership changes in recent months, including the appointment of Dr. Malte Peters as President and CEO in January 2026, succeeding Dr. Barbara Weber. Philippe Serrano, Pharm.D., was named Chief Regulatory Officer, and Sung Lee joined the Board of Directors, strengthening the company's regulatory and governance expertise as it advances toward pivotal trials.
Tango's shares have been volatile, typical of clinical-stage biotechnology companies, but the 7.4% gain on earnings day suggests investors are increasingly focused on the company's execution capabilities and the upcoming data readouts that could validate its synthetic lethality platform. With cash secured through 2028 and multiple clinical catalysts on the horizon, the company appears positioned to advance its pipeline without the near-term funding concerns that often pressure smaller biotech stocks.